Antihypertensive medication
ApprovedSmall molecule
Antihypertensive medication is one of 54 small molecule programs targeting Transient Ischemic Attack. It is currently in Approved.
3
Indications
4
Total Trials
0
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
37 competitors in Coronary Atherosclerosis
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Colcrys
Alnylam PharmaceuticalsApproved
Mounjaro
Eli LillyApproved
Actos
TakedaApproved
Precose
BayerApproved
Benicar
CCosette Pharmaceuticals, Inc.
Approved
Januvia
ZZydus Therapeutics Inc.
Approved
Tekturna
Tibotec Pharmaceuticals, IrelandApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Altoprev
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Coronary Atherosclerosis1 trial
Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT)
Unknown status·—·Phase 4·NCT02360956·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Antihypertensive medication. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity of Alberta